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ABSTRACT 
Objective: Present study deals with improvement in dissolution and bioavailability of poorly water soluble Lamotrigine (Lamo), an antiepileptic 
drug (AED) of phenyltriazine class. Formulation of poorly water soluble drug for oral delivery is one of the biggest challenge. Amongst all the 
approaches, the novel solid dispersion (SD) technique known as hot melt extrusion (HME) has found to be the most widely used method in 
improving dissolution and bioavailability.  
Methods: Dissolution enhancement of Lamo were done by HME technology where crystalline form of API is converted to amorphous form using 
hydrophilic polymer Kollidon VA64. Plasticizers like Polyethylene glycol (PEG 4000), polyoxyl 35 castor oil (Cremophor EL) and Sorbiton 
monolaurate (Montane 20PHA) were used. Physical blends of drug, polymer and plasticizer were prepared in the ratio of 1:1:0.1. These physical 
mixtures were subjected to melt and the resultant formulations were subjected to physical characterization, dissolution, permeability and in vivo 
testing. Pharmacokinetics of Lamo was studied in rats. Drug efflux pump like P-glycoprotein (P-gp) was recognized to posses’ functional role in 
determining the pharmacokinetics of drugs.  
Results: Drug release showed the similar profile for all the HME formulations while the permeability studies showed improved permeability of 
formulations containing Montane 20PHA. In comparison to Non HME, HME formulations showed a significant enhancement in permeability. SD 
prepared by Cremophor EL resulted in 765.22% enhancement in extent of absorption.  
Conclusion: HME technology could be a promising formulation approach to enhance the dissolution and bioavailability of Lamo.  
Keywords- Lamo, HME, In vivo, Kollidon VA64, Permeability. 
 
INTRODUCTION 
Lamo is an AED of the phenyltriazine class. Its chemical name is 3, 5-
diamino-6-(2,3-dichlorophenyl)-as-triazine [1], Lamo is very slightly 
soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M 
Hydrochoric acid (HCl) (4.1 mg/mL at 25ºC) [1]. Lamo belongs to 
the biopharmaceutical classification system (BCS) Class II, [2] for 
such hydrophobic compound, poor solubility would result in a slow 
dissolution and hence low oral bioavailability, which may limit its 
further clinical application. 
Majority of the drugs are administered by the preoral route. Many 
hurdles starting from drug dissolution in gastrointestinal fluid to first 
pass metabolism are due to various physicochemical and 
biopharmaceutical problems. It was recently identified that drug efflux 
pumps like P-gp are playing major role in altering the pharmacokinetics 
of various drugs and particularly associated with poor bioavailability in 
co-ordination with gut wall metabolism. Thus, a deep insight and 
thorough understanding of P-gp, its physiological and biochemical role in 
effluxing drugs is worthwhile, in order to have an opportunity to 
improve the bioavailability of drugs restricted by P-gp [3]. 
Improved clinical efficacy of various drugs observed by P-gp 
inhibition, P-gp inhibitors are gaining recognition to improve 
bioavailability by inhibiting P-gp in intestine, brain, liver and kidneys. 
P-gp can be inhibited (i) by blocking drug binding site either 
competitively. Non-competitive or allosterically; (ii) by interfering ATP 
hydrolysis; and (iii) by altering integrity of cell membrane lipids [3]. 
The bioavailability enhancement of poorly water soluble drugs by 
use of Pgp inhibitors finds to be improving by use of various 
plasticizers. Out of all the plasticizers of this study Cremophor EL [4] 
have been used as Pgp inhibitor for this study. Lamo is a strong 
substrate of Pgp activity. Inhibition of Pgp activity improves 
intestinal absorption and tissue distribution while reducing the 
substrate metabolism and its elimination. SD technique namely the 
HME was used for the preparation of formulations which were 
further subjected to pharmacokinetic study. Plasticisers are included 
to the polymers to facilitate thermal processing, to modify drug 
release from polymeric system and enhance mechanical properties 
and surface appearance of dosage form. When plasticisers are added 
to the polymers the flexibility of the polymers is increased by 
increasing the intermolecular separation of polymer molecules 
which results in reduction in glass transition temperature (Tg), 
polymer melt viscosity and tensile strength [5]. 
Various approaches are available to improve dissolution rate of 
poorly water-soluble drug, including the use of surfactants, inclusion 
complexation, drug micronization into an amorphous form and SD. 
[6] In the SD, the drug may be dispersed or solubilized within a 
polymeric carrier at molecular levels or in the amorphous state, and 
provide a large surface which leads to significant enhancement in 
the dissolution process. The improvement in dissolution is mainly 
attributed to the reduction in particle size, increase in surface area 
and reduction in crystallinity. Furthermore, no energy is required to 
breakup the crystal lattice of a drug during the dissolution process, 
and drug solubility and wettability may be improved by surrounding 
hydrophilic polymers used in SD. In comparison with traditional 
methods for preparation of SD, HME is a promising novel technology 
[7] for improving the bioavailability of water insoluble drugs, and 
presents many advantages for pharmaceutical applications. It can be 
used as a continuous process with the absence of aqueous or organic 
solvents and subsequent drying steps, which makes scaling up 
easier. In addition, intense blending and agitation during the process 
prevents the aggregation of drug particles suspending in the molten 
polymer, leading to a more homogeneous dispersion of fine 
particles. However, not all the thermal plastic polymer carriers are 
compatible with the drugs and suitable carriers as well, the 
drug/polymer ratio for a specific drug need to be optimized. In the 
present studies, we attempted to improve dissolution and 
bioavailability of Lamo by preparation of SD with HME technique. 
Hydrophilic polymer with certain Tg and backbones will be used to 
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prepare SD. Further pharmacokinetics of Lamo in rats was 
investigated to evaluate the in vivo performance of prepared SD. 
MATERIALS AND METHODS 
Materials 
Lamo was obtained as a gift sample from Emcure Pharmaceuticals 
ltd (Pune) and all other chemicals were obtained from the college 
source. 
Animals: Wistar Rats ranging from about 230-290g body weight 
approximately were used in the study. 
Prior consent approval was taken from the animal ethical 
committee. In vivo study protocols were approved by the 
Institutional Animal Ethics Committee (Regd. No RCPIPER/IAEC/07-
2013-14).  
Methods 
Optimization of drug: polymer ratio 
Solubility of Lamo and polymer was checked in different solvents 
such as methanol, ethanol and water. Both the drug and polymer 
were soluble in ethanol and hence selected as solvent for 
optimization of drug: polymer ratio. Drug and polymer (1:1 to 1:5) 
were solubilized in ethanol. The obtained solution was then poured 
into petri plates and films were cast [8] by the solvent evaporation 
method and were observed after 24 hrs at room temperature for 
their appearance. 
Preparation of HME and NHME formulation 
Different concentrations of plasticizers in the range of 10%w/w - 
30%w/w of polymer quantity were studied. Physical mixture of 
drug, polymer and plasticizer were subjected to melt extrusion 
process. The HME process was carried out using Thermo Scientific 
Prism Lab Model co-rotating intermeshing twin screw extruder with 
L/D of 40/1. [9] The screw speed was adjusted to 100 rpm resulting 
in residence time in the extruder of less than 1 min along with the 
barrel (melting zone) temperature of 220ºC [11]. Physical mixtures 
of various formulations were passed through the hot melt extruder. 
Melt extrudates were cooled at room temperature. Extrudes were 
milled using the hammer mill, involving coarse milling, fine milling 
and screening. Milled HME granules were then lubricated and 
subsequently compressed into tablets. NHME formulation was 
prepared by direct compression method. 
Solubility 
Solubility of Lamo was measured in distilled water. An excess 
amount of the drug was added to 50 ml conical flask and was kept 
under shaking for 72 hrs (Rotary shaker, Biomedica). Saturated 
solution was filtered through 0.45 μ membrane filter, absorbance of 
filtered solutions were determined and amount of drug solubilized 
was calculated. 
Dissolution [12] 
Tablets were evaluated for dissolution testing using:  
Medium: 0.1 N HCl; 900 mL 
Apparatus 2: 50 rpm 
Time: upto 45 min 
Permeability studies 
The prepared tablets were subjected to in vitro permeability test 
using dialysis membrane LA401 [13, 14]. Where the tablets were 
placed in the dialysis membrane along with the dissolution medium. 
This membrane tube was then introduced into the vessel just above 
the paddle and below the upper level of dissolution medium. 
Medium: 0.1 N HCl; 900 mL 
Apparatus 2: 50 rpm 
Time: up to 7 hrs 
In vivo studies 
pharmacokinetics evaluation of Lamo+Kollidon VA64+PEG4000 
(1:1:0.1), Lamo+Kollidon VA64+ Cremophor EL (1:1:0.1) and 
Lamo+Kollidon VA64+Montane 20PHA (1:1:0.1) optimised SD were 
used for in vivo studies in rats weighing 230-290 gm (n=4) of either 
sex at a dose equivalent to 50 mg/kg Lamo in comparison to Lamo 
pure drug. In vivo study protocols were approved by the 
Institutional Animal Ethics Committee (Regd. No RCPIPER/IAEC/07-
2013-14).  
Collection of blood sample: [15] 
200 µL blood samples were collected (into eppendorf tubes 
containing 20 µL of heparin solution) through tail vein from rats 
under light ether anesthesia at 30 min, 1 hour, 3 hour, 5 hour and 8 
hour after oral administration. 
Drug solution 
Lamo 10 mg/mL suspension in 0.5% carboxy methyl cellulose 
(CMC*) was prepared immediately before administration. Polymeric 
formulations were prepared as 20 mg/mL suspensions in 0.5 % 
CMC* immediately before administration. 
Dose 
50mg/kg of Lamo oral (As in Table 1) 
 
Table 1: Lamo doses to rats 
Rat No Body weight (G) Dose (ml) at 50 mg/kg Study group 
1.  267 1.34 Lamo 
2.  248 1.24 Lamo 
3.  254 1.27 Lamo 
4.  243 1.22 Lamo 
5.  276 1.38 FormulationL1 
6.  255 1.28 FormulationL1 
7.  268 1.34 FormulationL1 
8.  274 1.37 FormulationL1 
9.  244 1.22 FormulationL2 
10.  250 1.25 FormulationL2 
11.  278 1.39 FormulationL2 
12.  267 1.34 FormulationL2 
13.  245 1.23 FormulationL3 
14.  263 1.32 FormulationL3 
15.  264 1.32 FormulationL3 
16.  254 1.27 FormulationL3 
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Table 2: Preparation of standard solution in plasma 
Std drug solution (prepared in Methanol) 
(μg/ml) 




Final concentration in 
Plasma (μg/ml) 
200 995 5 1 
200 990 10 2 
200 975 25 5 
200 963.5 37.5 7.5 
2000 995 05 10 
2000 990 10 20 
 
Collection of blood samples 
200 µL blood samples were collected (into eppendorf tubes 
containing 20 µL of heparin solution) through tail vein from rats 
under light ether anesthesia at 30 min, 1 hour, 3 hour, 5 hour and 8 
hour after oral administration. 
Calibration curve: (As in figure 4) 
Calibration curve was done using plasma concentrations of 1, 2, 5, 
7.5, 10 and 20µg/ml. 
Preparation of standard solutions in plasma: (As in Table 2) 
Extraction procedure for the plasma samples and calibration curve 
related samples was as  follows 
Extraction procedure 
Blood samples were set aside for 20 minutes for coagulation. 
Coagulated blood samples were centrifuged at 1500 rpm for 10 
minutes for separation of serum. To 75 µL of serum sample, 10 µL of 
internal standard (100 ppm methylparaben solution in methanol) and 
30 µL of 1.0 N NaOH were added and this mixture was extracted with 
2.5 mL ethyl acetate twice. After addition of ethylacetate, each time the 
samples were vortexed for 5 minutes. The vortexed samples were 
centrifuged at 2000 rpm for 10 minutes. Ethylacetate layers were 
pooled and dried at room temperature. The dried ethylacetate extracts 
were reconstituted in 200 µL mobile phase, filtered through 0.2 µ filter 
and processed for HPLC analysis as stated below. 
HPLC analysis: [15] 
The HPLC system is Agilent 1200 HPLC, a gradient quaternary 
system (having four ports/reservoirs for mobile phase), a manual 
rheodyne injector of 20 µm loop with DAD detector (diode array 
detector system). 
• The HPLC column used in this study was Luna C 18 (2) stationary 
phase with 25 cm length, 4.6 mm internal diameter and 5 µm 
particle size.  
HPLC analysis of standard mixture of Lamo and methyl paraben 
The different methods were tried to obtain Lamo peak well resolved 
from the peak of internal standard Methyl Paraben. It is necessary that 
the standard mixture of Lamo and Methyl Paraben should pass the 
system suitability parameters like capacity factor, number of 
theoretical plates, tailing factor and resolution. With the optimized 
chromatographic parameters (stationary phase, mobile phase, flow 
rate, detection wavelength, volume of injection applied) the standard 
mixture of Lamo and Methyl Paraben was well resolved.  
• Initially, the sample of Lamo and Methyl Paraben were dissolved 
in Methanol (as all the compounds are soluble in Methanol). 
• Then, dilution of all the samples made with mobile phase [Lamo 
(5 ppm) + Methyl Paraben (5 ppm)] was performed. 
• The column was saturated with mobile phase with 1 mL/min flow 
rate. 
HPLC instrument 
Instrument Name: Agilent 1200 series with photodiode array 
detector 
HPLC details and procedure 
Column: Luna C18 (2) New Column 
Mobile Phase: Methanol: Water (80:20, v/v) 
Flow rate: 1 mL/min 
Wavelength of detection: 286 nm 
RESULTS AND DISCUSSION 
Based on film casting method 1:1 ratio of Drug: Polymer was 
optimized as no recrystallization of API was observed in the film 
after 48 hours of storage. Recrystallization was observed in sample 
of pure drug only. Based on the observations it can be concluded 
that 1:1 drug: polymer ratio was sufficient to hold the amorphous 
form of API in solid solution. The use of 10%w/w concentration of 
plasticizers gave same solubility enhancement as compared to 
20%w/w and 30%w/w concentration. So 10%w/w concentration of 
plasticizer was optimized in the formulations and only these 
formulations were subjected for further study like dissolution, 
permeability and in vivo study. Foremost objective of this study is to 
enhance solubility of Lamo, complete melting of drug in polymeric 
matrix is necessary, so temperature of melting zone was set at 220ºC 
as API melting point is 216ºC - 218ºC. Polymer can’t degrade at HME 
processing temperature as its degradation temperature is above 
230ºC. HME processing time was maintained less than 1 min with 
the help of screw speed so as to avoid degradation of drug and 
polymer as residence time is directly related to degradation.  
Kollidon VA 64 is a hydrophilic polymer and form a gel on the 
surface of tablet when comes in contact with dissolution media. 
Tablets prepared with HME technology shows disintegration pattern 
by erosion mechanism.  
The disintegration time (DT) of these tablets was two times more than 
DT of NHME formulation. At first time point dissolution of HME 
formulations was slower than NHME formulations, due to higher DT of 
tablets, thereafter both approaches shows similar dissolution profiles. 
As Lamo is slightly soluble in 0.1N HCl, complete release (Figure 1) 
was observed at 45 min time point. Different types of plasticizers did 
not show any effect on dissolution rate or present dissolution method 
was unable to discriminate the formulation changes (types of 
plasticizers) in dissolution profile. So, author had taken support of in 
vitro permeability study to evaluate the effect of type of plasticizers. 
Dissolution results are interpreted with the help of different 
dissolution models. 
 
Table 3: Solubility studies 
10 % Plasticizer 
Sample Drug  HME with PEG 4000 HME with Cremophor EL HME with Montane 20 PHA 
Solubility (µg/mL) 70.15 100.09 370.91 310.66 
Solubility of formulation containing 10% cremophor EL shows maximum improvement in solubility followed by Montane 20PHA and PEG4000. 
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Fig. 1: Dissolution comparison of HME and NHME formulations 
 
Table 4: Model fitting 
 L1 (10% PEG 4000) L2 (10% CREMOPHOR EL) L3 (10% MONTANE 20) 
 R K n R K n R K n 
Matrix 0.8736 0.0402 - 0.8818 0.0408 - 0.8787 0.0401 - 
T-test 4.015 passes - 4.181 passes - 4.116 (Passes) - 
Peppas 0.9797 0.1062 0.1951 0.9926 0.1039 0.2071 0.9784 0.1049 0.1978 
T-test 10.927 passes - 18.219 passes - 10.576 (Passes) - 
Where R=regression coefficient, k= kinetic constant, n= diffusion exponent 
 
In Peppas model when the release exponent n ≤ 0.5 by Fickian 
diffusion release from slab (non swellable matrix) means that 
drug release followed, by both diffusion and erosion controlled 
mechanisms [16, 17]. Same drug release pattern has been 
observed in present study for tablets prepared by HME 
technology. 
 
Table 5: Comparative values of plasticizers 
 ST (mN/m) Hydroxyl value HLB 
(PEG 4000) 44([20] 25-32) ([20] 18.5) ([20]) 
(Cremophor EL) 40.9 ([19] 65-78) ([19] 12-14) ([19]
(Montane 20PHA) 
) 
28([18] 159-169 ) ([18] 8.6 ) ([18]) 
 
 
Fig. 2: Permeability comparison HME and NHME formulations 
 
Formulation with 10% Montane 20PHA shows improvement in, in 
vitro permeability as compared to formulations containing 10% 
Cremophor EL and 10% PEG 4000. NHME formulation shows lower 
permeability than all HME formulations. Surprisingly in vitro 
permeability enhancement was observed in formulation prepared 
by 10% Montane 20 irrespective of lower Hydrophlic Lipophilic 
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Balance (HLB) value, which can be justified based on the other 
properties of plasticisers like hydroxyl value and surface tension 
(ST). Hydroxyl value of plasticizers may play an important role in 
Critical Micelle Concentration (CMC). Higher is the hydroxyl value 
more will be the hydrophilicity of plasticizer. Montane 20PHA has a 
higher hydroxyl value of 159-169 than hydroxyl value of Cremophor 
EL of 67-78 and PEG 4000 of 25-32 [19, 20] which may play an 
important role to improve solubility and ultimately permeability. K 
values of Matrix and Peppas models passes. Based on R value it can 
be concluded that Peppas is the best fitted model for all the 3 
formulations. Also lower ST of plasticizer can help the drug 
penetration in solvent or media to enhance solubility. 
Lower the melt viscosity of polymer more will be the mixing 
efficiency of API and polymer. Use of plasticizers in formulation 
lower the Tg of polymer with increased intermolecular 
separation in polymer chains which ultimately improves the 
molecular level dispersion of API in polymer bed. NHME tablets 
shows lower in vitro permeability compared to all HME 
formulations (Figure 2), even though having almost similar 
profile in dissolution study. Increase in, in vitro solubility and 
permeability by HME technology may increase the in vivo 
bioavailability which may lead to reduction in some fold of dose. 
Linearity of the method was in the concentration range 1- 20 μg/mL 
of Plasma (Figure 3).  
 
 
Fig. 3: Calibration curve 
Plasma concentrations of lamo following the oral administration of pure drug and its solid dispersions prepared by HME technology is shown in Fig. 4. 
 
 
Fig. 4: Animal study 
Pharmacokinetics parameters estimated are summarized in Table 6. 
 
Table 6: Pharmacokinetic parameters of Lamo 
 Parameters 
Samples 







Lamo 0.5 2.8 10 23 12 
L1 (10% PEG 4000) 0.63 3.3 14 30 11 
L2 (10% Cremophor EL) 0.5 4.9 24 199 55 
L3 (10% Montane 20 PHA) 0.5 4.6 18 44 13 
Lamo was found to be absorbed rapidly when given orally, and a highest peak plasma concentration (Cmax) 4.9 μg/mL was observed at 0.5 hrs after 
administration of L2 formulation (10% Cremophor EL). 
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All the pharmacokinetics parameters namely Cmax, Tmax and (AUC)0-∞ 
indicated rapid and higher absorption of Lamo when administered as 
solid dispersion (L2) prepared using 10% Cremophor EL. AUC0-∞ was 
also much higher in case of SD prepared with 10% Cremophor EL when 
compared to NHME and other HME formulations. AUC0-∞ was increased 
from 23 hr*µM (for pure drug) to 30 hr*µM, 199 hr*µM and 44 hr*µM 
for L1, L2 and L3 respectively. Extent of absorption was increased by 
30.43%, 765.22% and 91.30% in L1, L2 and L3 formulations 
respectively. Noticeable boost in absorption 
S. No. 
of L2 formulation was 
observed due to p-gp inhibition activity by Cremophor EL. Lamo is a 
strong substrate of P-gp activity, so P-gp inhibitor like Cremophor EL 
enhanced its in vivo bioavailability to great extent. As a measure of 
hydroxyl groups in a surfactant, the hydroxyl value is an indicator of the 
hydrophilic character [21]. In this study, it has been observed that 
solubility of drug increases as hydroxyl value increases. In, in vivo study 
the extent of absorption increases as hydroxyl value of plasticizers 
increases. Plasticizers like Montane 20 PHA and PEG 4000 improved the 
solubility and permeability of Lamo as compare to pure drug due to HME 
technology. The bioavailability enhancement of Lamo in L2 formulation 
is a cumulative effect of HME technology and P-gp activity of Cremophor 
EL. So it is difficult to calculate the exact improvement in bioavailability 
due to HME technology. 
CONCLUSION 
SD prepared using 10% Montane 20 PHA and 10% Cremophor EL 
improved the in vitro permeability and bioavailability of Lamo 
respectively. This study reveals the solubility enhancement by HME 
technology and bioavailability enhancement was mainly achieved by 
plasticizer having P-gp inhibition activity. Other plasticizers like PEG 
4000 and Montane 20PHA improved the solubility and 
bioavailability due to HME technology only. HME technology 
improved the physicochemical and pharmacokinetic parameters 
which confirmed the versatile application of this technology in 
pharmaceutical development of poorly water soluble drugs. 
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ABBREVIATIONS 
Word Abbreviation 
1 Lamotrigine Lamo 
2 Antiepileptic Drug AED 
3 Solid Dispersion SD 
4 Hot Melt Extrusion HME 
5 Polyethylene Glycol PEG 
6 Paraglycoprotein P-gp 
7 Biopharmaceutical Classification system BCS 
8 Hydrochloric Acid HCl 
9 Glass Transition temperature Tg 
10 Carboxy Methyl Cellulose CMC* 
11 Critical Micelle Concentration CMC 
12 Surface Tension ST 
13 Hydrophilic Lipophilic Balance HLB 
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